Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Queensland Health
McKinsey
Cipla
Johnson and Johnson
Covington
Moodys
Colorcon
McKesson
UBS

Generated: January 17, 2018

DrugPatentWatch Database Preview

Ceftolozane sulfate; tazobactam sodium - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for ceftolozane sulfate; tazobactam sodium and what is the scope of ceftolozane sulfate; tazobactam sodium patent protection?

Ceftolozane sulfate; tazobactam sodium
is the generic ingredient in one branded drug marketed by Cubist Pharms Llc and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ceftolozane sulfate; tazobactam sodium has forty-eight patent family members in twenty-seven countries.

One supplier is listed for this compound.
Summary for ceftolozane sulfate; tazobactam sodium
International Patents:48
US Patents:6
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 3,116
Drug Prices:see low prices
DailyMed Link:ceftolozane sulfate; tazobactam sodium at DailyMed
Pharmacology for ceftolozane sulfate; tazobactam sodium

US Patents and Regulatory Information for ceftolozane sulfate; tazobactam sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;IV (INFUSION) 206829-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;IV (INFUSION) 206829-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;IV (INFUSION) 206829-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;IV (INFUSION) 206829-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;IV (INFUSION) 206829-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;IV (INFUSION) 206829-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;IV (INFUSION) 206829-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;IV (INFUSION) 206829-001 Dec 19, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for ceftolozane sulfate; tazobactam sodium

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,044,485 Ceftolozane antibiotic compositions ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for ceftolozane sulfate; tazobactam sodium

Supplementary Protection Certificates for ceftolozane sulfate; tazobactam sodium

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016 00004 Denmark ➤ Subscribe PRODUCT NAME: CEFTOLOZAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT ET SVOVLSYRESALT; REG. NO/DATE: EU/1/15/1032/001 20150922
2016 Austria ➤ Subscribe PRODUCT NAME: CEFTOLOZAN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE EIN SCHWEFELSAEURESALZ; REGISTRATION NO/DATE: EU/1/15/1032/001 (MITTEILUNG) 20150922
0793 Netherlands ➤ Subscribe PRODUCT NAME: CEFTOLOZAAN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN IN HET BIJZONDER EEN ZWAVELZUURZOUT; REGISTRATION NO/DATE: EU/1/15/1032 20150922
2016 00004 Denmark ➤ Subscribe PRODUCT NAME: CEFTOLOZAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT ET SVOVLSYRESALT; REG. NO/DATE: EU/1/15/1032/001 20150922
90003-7 Sweden ➤ Subscribe PRODUCT NAME: CEFTOLOZAN ELLER ETT FARMACEUTISKT ACCEPTABELT SALT DAERAV, SPECIELLT ETT SVAVELSYRASALT; REG. NO/DATE: EU/1/15/1032 20150918
C0004 France ➤ Subscribe PRODUCT NAME: CEFTOLOZANE,EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,PLUS PARTICULIEREMENT UN SEL D'ACIDE SULFURIQUE; REGISTRATION NO/DATE: EU/1/15/1032 20150922
2015000113 Germany ➤ Subscribe PRODUCT NAME: CEFTOLOZAN ODER EIN PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, INSBESONDERE EIN SCHWEFELSAEURESALZ; REGISTRATION NO/DATE: EU/1/15/1032/001 20150918
943 Luxembourg ➤ Subscribe PRODUCT NAME: CEFTOLOZANE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, EN PARTICULIER UN SEL D'ACIDE SULFURIQUE (ZERBAXA); FIRST REGISTRATION: 20150922
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Accenture
Chinese Patent Office
Citi
Moodys
Merck
Dow
McKinsey
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot